CSIMarket
 


Kalvista Pharmaceuticals Inc   (KALV)
Other Ticker:  
 

Kalvista Pharmaceuticals Inc 's Quick Ratio

KALV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2023, Quick Ratio fell to 6.21 below Kalvista Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 162 other companies have achieved higher Quick Ratio than Kalvista Pharmaceuticals Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 362 to 473.

Explain Quick Ratio?
How much Cash & cash equivalents KALVīs has?
What are KALVīs Current Liabilities?


KALV Quick Ratio (Oct 31 2023)
II. Quarter
(Jul 31 2023)
I. Quarter
(Apr 30 2023)
IV. Quarter
(Jan 31 2023)
III. Quarter
(Oct 31 2022)
II. Quarter
Y / Y Current Liabilities Change 61.29 % 48.92 % 31.57 % 22.17 % 12.09 %
Y / Y Cash & cash equivalent Change -15.62 % -13.25 % -10.12 % -11.86 % -41.72 %
Quick Ratio MRQ 6.21 9.47 10.71 16.28 11.88
KALV's Total Ranking # 473 # 362 # 344 # 155 # 336
Seq. Current Liabilities Change 27.62 % -6.7 % 32.19 % 2.48 % 17.83 %
Seq. Cash & cash equivalent Change -16.3 % -17.48 % -12.99 % 40.41 % -13.94 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 163
Healthcare Sector # 267
Overall Market # 473


Quick Ratio Statistics
High Average Low
31.49 12.54 0.29
(Jul 31 2021)   (Mar 31 2015)




Financial Statements
Kalvista Pharmaceuticals Inc 's Current Liabilities $ 17 Millions Visit KALV's Balance sheet
Kalvista Pharmaceuticals Inc 's Cash & cash equivalent $ 103 Millions Visit KALV's Balance sheet
Source of KALV's Sales Visit KALV's Sales by Geography


Cumulative Kalvista Pharmaceuticals Inc 's Quick Ratio

KALV's Quick Ratio for the trailling 12 Months

KALV Quick Ratio

(Oct 31 2023)
II. Quarter
(Jul 31 2023)
I. Quarter
(Apr 30 2023)
IV. Quarter
(Jan 31 2023)
III. Quarter
(Oct 31 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth 61.29 % 48.92 % 31.57 % 22.17 % 12.09 %
Y / Y Cash & cash equivalent TTM Growth -15.62 % -13.25 % -10.12 % -11.86 % -41.72 %
Quick Ratio TTM 10.12 11.85 13.45 14.99 16.34
Total Ranking TTM # 227 # 217 # 208 # 202 # 218
Seq. Current Liabilities TTM Growth 27.62 % -6.7 % 32.19 % 2.48 % 17.83 %
Seq. Cash & cash equivalent TTM Growth -16.3 % -17.48 % -12.99 % 40.41 % -13.94 %


On the trailing twelve months basis Due to growth in Current Liabilities in the II Quarter 2023 to $16.60 millions, cumulative Quick Ratio decreased to 10.12 below the Kalvista Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 476 other companies have achieved higher Quick Ratio than Kalvista Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 3123, from total ranking during the twelve months ending first quarter 2023 at 3230.

Explain Quick Ratio?
How much Cash & cash equivalents KALVīs has?
What are KALVīs Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 477
Healthcare Sector # 963
Within the Market # 473


trailing twelve months Quick Ratio Statistics
High Average Low
23.41 10.23 2.52
(Jan 31 2022)   (Jul 31 2018)




Companies with similar Quick Ratio in the quarter ending Oct 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioOct 31 2023 MRQ Cash & cash equivalentOct 31 2023 MRQ Current Liabilities
Cadrenal Therapeutics Inc   16.91 $ 9.109  Millions$ 0.539  Millions
Day One Biopharmaceuticals Inc   16.57 $ 405.538  Millions$ 24.475  Millions
Lyell Immunopharma Inc   16.41 $ 575.431  Millions$ 35.064  Millions
Compass Pathways Plc  16.18 $ 248.369  Millions$ 15.350  Millions
Inozyme Pharma Inc   15.68 $ 192.442  Millions$ 12.275  Millions
Acrivon Therapeutics Inc   15.28 $ 142.090  Millions$ 9.299  Millions
Agios Pharmaceuticals Inc   14.80 $ 647.488  Millions$ 43.761  Millions
Larimar Therapeutics Inc   14.58 $ 95.590  Millions$ 6.558  Millions
Dianthus Therapeutics Inc   14.52 $ 189.870  Millions$ 13.079  Millions
Nuvalent Inc   14.20 $ 413.258  Millions$ 29.103  Millions
Prelude Therapeutics Inc  14.04 $ 230.506  Millions$ 16.418  Millions
Verve Therapeutics Inc   14.03 $ 485.226  Millions$ 34.575  Millions
Minerva Neurosciences Inc   14.00 $ 46.904  Millions$ 3.350  Millions
Rezolute Inc   13.72 $ 98.730  Millions$ 7.195  Millions
Crinetics Pharmaceuticals Inc   13.71 $ 554.653  Millions$ 40.463  Millions
Dynavax Technologies Corporation  13.28 $ 720.416  Millions$ 54.264  Millions
Kezar Life Sciences Inc   13.09 $ 218.205  Millions$ 16.672  Millions
Rocket Pharmaceuticals Inc   13.06 $ 437.171  Millions$ 33.476  Millions
Briacell Therapeutics Corp   13.04 $ 13.646  Millions$ 1.047  Millions
Vistagen Therapeutics Inc   12.93 $ 37.608  Millions$ 2.910  Millions
Rallybio Corporation  12.91 $ 121.384  Millions$ 9.402  Millions
Io Biotech Inc   12.75 $ 165.501  Millions$ 12.985  Millions
Relmada Therapeutics Inc   12.62 $ 106.267  Millions$ 8.422  Millions
Prothena Corporation Public Limited Company  12.57 $ 670.897  Millions$ 53.370  Millions
Biomea Fusion Inc   12.28 $ 199.090  Millions$ 16.210  Millions
Ligand Pharmaceuticals Incorporated  12.11 $ 190.502  Millions$ 15.727  Millions
Oric Pharmaceuticals Inc   12.00 $ 227.296  Millions$ 18.944  Millions
Anebulo Pharmaceuticals Inc   11.89 $ 8.521  Millions$ 0.717  Millions
Ovid Therapeutics Inc   11.70 $ 87.072  Millions$ 7.439  Millions
Gh Research Plc  11.70 $ 78.420  Millions$ 6.701  Millions

Date modified: 2023-12-08T14:04:57+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com